P-21

P-21 (also designated P021 or Peptide 6) is a synthetic tetrapeptide mimetic of ciliary neurotrophic factor (CNTF), a neuroprotective cytokine that promotes neuronal survival, differentiation, and plasticity. CNTF itself cannot be used therapeutically due to poor pharmacokinetics, inability to cross the blood-brain barrier, and severe systemic side effects including cachexia. P-21 was developed by identifying the minimal pharmacophore of CNTF — a DGGL tetrapeptide corresponding to residues 147-150 — and enhancing it with an adamantane modification that confers lipophilicity, metabolic stability, and blood-brain barrier permeability.

P-21 is a purely preclinical compound with an entirely animal-based evidence base. No Phase 1 or Phase 2 human trials have been published. It is sold by research peptide vendors and is not approved for any clinical use. Safety in humans has not been assessed.

P-21's primary mechanism is inhibition of the leukemia inhibitory factor (LIF) signaling pathway while simultaneously increasing BDNF expression in the hippocampus. This dual action — LIF pathway inhibition combined with BDNF upregulation — promotes the differentiation, maturation, and functional integration of newly born neurons (neurogenesis) in the adult dentate gyrus.

BDNF upregulation, mediated through CNTF pathway mimicry, downstream activates the TrkB receptor and its signaling cascades (MAPK, PI3K/AKT, PLCγ), which are the central drivers of synaptic plasticity, long-term potentiation, and cognitive function. Additionally, increased BDNF signaling reduces glycogen synthase kinase-3β (GSK-3β) activity via AKT phosphorylation, inhibiting tau hyperphosphorylation — directly targeting a key pathological process in Alzheimer's disease.

The adamantane modification at the C-terminus is critical for therapeutic utility: it dramatically increases membrane permeability and allows systemic (subcutaneous) administration to produce CNS effects, converting a peptide that would otherwise be peripherally confined into a BBB-penetrant neurotrophin mimetic.